A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

@article{Somlo2011API,
  title={A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer},
  author={George Somlo and Cynthia L Martel and Sean K. Lau and Paul Frankel and Christopher Ruel and Lin Gu and Arti Hurria and Cyril Chung and Thehang H Luu and R Garret Morgan and Lucille Leong and Mariana Koczywas and Michael Mcnamara and Christy Ann Russell and Susan E. Kane},
  journal={Breast Cancer Research and Treatment},
  year={2011},
  volume={131},
  pages={899-906}
}
Inhibition of the HER-2 pathway via the monoclonal antibody trastuzumab has had a major impact in treatment of HER-2 positive breast cancer, but de novo or acquired resistance may reduce its effectiveness. The known interplay between the epidermal growth factor receptor (EGFR) and HER-2 receptors and pathways creates a rationale for combined anti-EGFR and… CONTINUE READING